Enfortumab Vedotin

adc

Identifier: CI-DRUG-00000213
Entity page: /drug/enfortumab-vedotin ↗
Edges: 150

Neighbours: 18 cancers15 genes10 trials10 approvals
Drawn: 53 of 53 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Enfortumab Vedotin approved for …APPROVED_FOR14 of 10
→ approved for	Malignant Bladder Neoplasmcancer	supports	FDA ORIG	Malignant Bladder Neoplasm	1	Regulatory	openfda	graph →
→ approved for	Urinary Tract Neoplasmsubtype	supports	mesh_therapeutic_area

Enfortumab Vedotin targets …TARGETS15 of 16show all (up to 200)
→ targets	TUBB2A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB2B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB6	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1B	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1C	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA3E	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA1A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB4A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB8	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA3C	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBA4A	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	TUBB3	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	NECTIN4	—	BINDING AGENT	—	1	Curated	chembl	graph →
→ targets	TUBB1	—	INHIBITOR	—	1	Curated	chembl	graph →

Enfortumab Vedotin targets …TARGETS15 of 16show all (up to 200)

→ targets

TUBB2A

—

INHIBITOR

—

Curated

Enfortumab Vedotin investigated for …INVESTIGATED_FOR5 of 5
→ investigated for	Urinary Tract Neoplasmsubtype	unknown	4	Urinary Tract Neoplasm	1	Curated	chembl	graph →
→ investigated for	Transitional Cell Carcinomahistology	unknown	4	Transitional Cell Carcinoma	1	Curated	chembl	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Bladder Neoplasmsubtype	unknown	3	Bladder Neoplasm	1	Curated	chembl	graph →
→ investigated for	Pancreatic Neoplasmsubtype	unknown	2	Pancreatic Neoplasm	1	Curated	chembl	graph →

Enfortumab Vedotin investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 47show all (up to 200)
→ investigated in trials for	Urothelial Carcinoma 22 trials (19 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Urothelial Carcinoma	22	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Bladder Neoplasmcancer 18 trials (15 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Bladder Neoplasm	18	Observed	clinicaltrials	graph →
→ investigated in trials for	Bladder Neoplasmsubtype 8 trials (5 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Bladder Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Transitional Cell Carcinomahistology 6 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Transitional Cell Carcinoma	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Pelvis and Ureter Urothelial Carcinoma 5 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Pelvis and Ureter Urothelial Carcinoma	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Bladder Urothelial Carcinoma 4 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Bladder Urothelial Carcinoma	4	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Ureter Neoplasm 3 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Ureter Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Ureter Neoplasm 3 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Ureter Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Bladder Adenocarcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Bladder Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Bladder Squamous Cell Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Bladder Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Urethral Neoplasm 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Urethral Neoplasm	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Muscle Invasive Bladder Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Muscle Invasive Bladder Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Muscle Invasive Bladder Urothelial Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Muscle Invasive Bladder Urothelial Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Penile Squamous Cell Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Penile Squamous Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Renal Pelvis and Ureter Carcinoma 2 trials (2 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Renal Pelvis and Ureter Carcinoma	2	Observed	clinicaltrials	graph →

Enfortumab Vedotin studied in …STUDIED_INderived10 of 72show all (up to 200)
→ studied in	NCT07421700Phase 1/Phase 2 · recruiting Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer · 72 trials list this drug (58 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07217496Phase 1 · not yet recruiting N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer · 72 trials list this drug (58 active)	—	—	Urothelial Carcinoma,Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07475806Phase 2 · recruiting A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder · 72 trials list this drug (58 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04225117Phase 2 · active not recruiting A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) · 72 trials list this drug (58 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →
→ studied in	NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · 72 trials list this drug (58 active)	—	—	Urothelial Carcinoma,Bladder Urothelial Carcinoma,Malignant Bladder Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06906822Phase 2 · active not recruiting PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients · 72 trials list this drug (58 active)	—	—	Melanoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05239624Phase 2 · recruiting Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer · 72 trials list this drug (58 active)	—	—	Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06394570Phase 1/Phase 2 · recruiting Enfortumab Vedotin and Stereotactic Radiation for Localized, Cisplatin Ineligible Muscle Invasive Bladder Cancer · 72 trials list this drug (58 active)	—	—	Malignant Bladder Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · 72 trials list this drug (58 active)	—	—	Bladder Urothelial Carcinoma,Invasive Bladder Giant Cell Urothelial Carcinoma,Malignant Bladder Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT07825753Phase 2 · not yet recruiting Protein-Matched ADC or PDC Umbrella Trial in Advanced Pancreatic and Breast Cancer · 72 trials list this drug (58 active)	—	—	not mapped	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths